30
Jun

The gene therapy pioneer bluebird bio has snapped up a biotech outfit skilled in gene-editing and cell-signaling tech in a deal valued at up to $156 million, including about $16 million worth of its stock.

…read more

Source: Bluebird snares gene-editing tech in $156M buyout deal

    

0 No comments